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Objective: Quality of life data in cancerology are often difficult to summarize due to missing data and difficulty to
analyze the pattern of evolution in different groups of patients. The aim of this work was to apply a new methodology
to construct Quality of Life (QoL) change patterns within patients included in a clinical trial comparing to regimen of
treatment in locally advanced eosogastric cancer.
Materials and methods: In this trial, QoL was assessed every 2 months by self-reported EORTC QLQ-C30 questionnaire.
Physical dimension scores were analyzed. After multiple imputation of missing data, 27 statistical measures aiming to
describe the variation of QoL measures among follow-up were computed for each patient. Based on these measures,
patient were grouped into homogenous groups in terms of QoL variation pattern using a K-Means classification
method. The mean QoL score at each time was graphically represented in each obtained pattern. Finally, clinical
characteristic of patients in each pattern of QoL were described and compared.
Results: The trial included 416 patients and 1023 questionnaire were collected. 74 % of patients were male with
a mean ± SD age of 62 ± 11 years. 43 % of scores were missing. Patients were grouped into four classes of homogeneous
QoL variation patterns. 1) a Pattern of 24 (6 %) patients showing improvement in QoL with a mean variation of +10.7
points on the 0–100 scale, 2) a Pattern of 171 (41 %) patients showing a stability 3) two Patterns of 78 (19 %) and 143
(34 %) patients respectively showing a deterioration of QoL with a mean variation of −67.2 and −67.6, respectively. There
were no difference between patterns in terms of gender or age. Patients within “degradation” pattern had significantly
lower performance status (p = 0.015), higher severe after-effects rate (p < 10-3) and death rate (p < 10-3).
Conclusion: This work opens up perspectives for longitudinal data analysis with a high probability of missing values
while providing a relevant graphical summary. Patterns of QoL evolution with clinical relevance may help to interpret
longitudinal QoL data in Cancer studies.
Keywords: Quality of life, Change patterns, Multiple imputation, ClusteringIntroduction
Gastrointestinal cancers are among the most frequent can-
cers in France [1, 2]. Metastatic or locally-advanced can-
cers have a bleak prognosis. The treatments proposed only
marginally improve survival, but allow progress in terms* Correspondence: catherine.quantin@chu-dijon.fr
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sential criterion for the evaluation of new treatments [6–8]
and a description of the evolution of patients’ feelings in
the context of aggressive therapy is becoming a systematic
secondary objective in phase III trials, and in a large num-
ber prognostic studies in routine practice [9, 10].
However, the analysis of QoL in patients is a very
complex process and the heterogeneity of patients’ per-
ception of their state of health often makes it difficult
for clinicians to interpret the objective results of studies.
We can first of all underline the subjective nature of the
information collected at different time points for eachis distributed under the terms of the Creative Commons Attribution 4.0
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the use of multidimensional measurement scales, each
dimension being summarized when possible by a com-
puted score. Finally, the repeated nature of the scores re-
corded per patient makes it almost impossible to avoid
missing data (MD) [11, 12]. The reasons for MD are
wide and varied, Rubin et al. proposed, in a theoretical
framework on missing data problems [13], a classifica-
tion system that is widely used in the methodological
literature [14–16]. According to this system, whatever
the reason for missing data, it can fit into one of the
three classes of missing data mechanisms. The nature of
the association between the probability of missing data
and other variables defines the three so-called missing
data mechanisms: 1/ A missing completely at random
(MCAR) mechanism occurs when the propensity for miss-
ing data on a particular variable is unrelated to other mea-
sured variables and to the would-be values of that variable,
2/ A missing at random (MAR) mechanism which holds
when the probability of missing data on a variable is related
to other variables, but not to the would-be values of the in-
complete variable, 3/ A missing not at random (MNAR)
mechanism that occurs when the probability of missing
data on a variable is related to the would-be value of
that variable (i.e., outcome-dependent missingness).
The impact of MD must be taken into account to at-
tenuate the non-negligible risk of bias [15, 17].
Nonetheless, taking this subjective element (QoL) into
account is particularly important with regard to the re-
sults of phase III therapeutic trials involving patients
with advanced gastrointestinal cancer for whom the ob-
jective to improve QoL is essential. Therefore, modeling
individual-level heterogeneity in QoL evolutions (aka
trajectories) remains a goal for exploratory and predic-
tion purpose, as does capturing the heterogeneity of in-
dividual QoL trajectories. For this, it may be of interest
to identify clusters or groups of these trajectories that
may reflect distinctive individual differences. These
groups must be described, presented and interpreted in
a way that is simple and understandable. The methods
used to analyze changes in longitudinal data have been
evolving steadily over the last twenty years or so and
notably since the use descriptive methods, which use
measurements of central trends (means, medians,…)
and thus eclipse the longitudinal nature of the data. We
can note, the contribution of growth curve models (also
known as mixed effects models, random coefficient
models, and multilevel models), which have allowed a
more precise description of the data. The approach in
our case would be to model population distribution of
trajectories based on continuous distributions (of scale
scores) in order to sort out individual factors accounting
for variation concerning, for example, the population. This
approach requires strong technical assumptions aboutdistribution (multivariate normal distribution) and the re-
sults remain difficult to interpret for the non-specialist
[18, 19]. Another contribution is due to the group-based
trajectory models (GBTM) which extend the previous
work with a qualitative approach to modeling individual
difference by identifying clusters of individuals with simi-
lar trajectories. Here, individual differences that may ex-
plain or at least predict individual-level heterogeneity can
be expressed in terms of groups’ differences [20]. When
datasets contain MNAR data, the model specification
based on the GBTM approach at its current stage of de-
velopment may not accommodate such a complex missing
data mechanism [20]. Today, even more sophisticated
methods make it possible to identify subgroups of QoL
change patterns from scale scores (quantitative variables)
and to elaborate specific hypotheses in each subgroup
of patients [21–23], thus making it possible to model
individual-level characteristics in these patterns. These
methods are becoming easier to use and provide easily
interpretable results. At the same time, methods to take
MD into account in the analysis of clinical studies are
being standardized [18, 24–28].
The aim of this work was to use these new methods
first to construct a typology of QoL change patterns
(CP) in the context of a phase III therapeutic trial in pa-
tients with locally-advanced and metastatic gastrointes-
tinal cancer, and secondly to describe identified patterns
using the variables collected.
Materials and methods
Study design of the phase III clinical trial (FFCD-0307)
We worked on data from a phase III clinical trial (FFCD-
0307) conducted between June 2005 and May 2010. The
results of this study are published in Guimbaud et al. [29].
It was a multicenter, randomized, open, prospective trial
that compared the efficacy of two sequential polyche-
motherapy strategies (FOLFIRI followed by Epirubicin-
Cisplatin-Capecitabine (ECX) versus ECX followed by
FOLFIRI) in patients with histologically confirmed, unre-
sectable, locally advanced or metastatic gastric or esopha-
gogastric junction adenocarcinoma.
Other inclusion criteria were age ≥18-years; measur-
able and/or assessable lesions according to RECIST cri-
teria [30]; WHO performance status (PS) ≤2; ability to
take oral medications; no previous palliative chemo-
therapy (≥6 months from adjuvant chemotherapy was
allowed); ≥3 weeks from previous radiotherapy; sufficient
bone marrow function; creatininemia ≤110 μmol/L; biliru-
binemia ≤35 μmol/L. Exclusion criteria were a history of
fluorouracil or anthracycline cardiotoxicity, cardiac or cor-
onary deficiency; known cerebral or meningeal metastasis;
other life-threatening cancer; being pregnant or breast-
feeding; inability to complete the European Organisation
for Research and Treatment of Cancer Quality of Life
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to plan regular follow-up for any reason. This trial
showed that time to treatment failure (TTF) was sig-
nificantly longer with FOLFIRI first-line compared to
ECX first-line therapy.
Collection of quality of life data in the phase III clinical trial
(FFCD-0307)
The secondary objective of the phase III clinical trial
(FFCD-0307) was to evaluate quality of life measured by
the EORTC-QLQ-C30 self-administered questionnaire.
The study design planned an evaluation of this question-
naire every 8 weeks.
EORTC QLQ-C30 Questionnaire
The QLQ-C30 is a questionnaire with 30 items, that
covers health issues, and applicable for all cancers. Of
those 30 items, 17 are grouped into 5 functional scales
or dimensions (physical, cognitive, role, emotional, and
social functioning) and one global health status/quality
of life scale. The remaining 13 items are scales related
symptoms (fatigue, nausea/vomiting, pain, dyspnea, diar-
rhea, insomnia, appetite loss, and constipation). The
questionnaire is validated in patients with gastric cancers
[31, 32]. For each scale, a score was calculated in two
steps according to a standardized method [32]: first, a
raw score was estimated as the average of items that
contributed to the scale. And then, a linear transform-
ation was used to standardize the raw score so that
scores ranged from 0 to 100. We focused our work on
the physical functioning scale with scores ranging from
0 (severe debilitation) to 100 (asymptomatic/best quality
of life). This scale is based on 5 items (corresponding to
questions 1 to 5 of the whole qlq-c30 questionnaire) and
the patients assessed for the previous week their abilities
to carry out certain everyday activities such as getting
dressed, taking care of personal hygiene, carrying a bag of
shopping or even going for a walk (see Additional file 1:
Annex 1 for the listing of the 1 to 30 items with answer
options).
Calculation of QoL change patterns
In this study, we included all of the patients previously
included in the phase III clinical trial (cf. study design).
However, as all of the patients did not complete the
whole questionnaire, we decided to use a data imput-
ation method to complete the missing data.
We considered a follow-up of approximately 13 months
after the randomization (corresponding to the first seven
measurements of the physical functioning scale score)
(QLQ-C30 PF2. Hereinafter, they will be noted T1, T2, …
T7 . An individual score patterns (ISP) was defined as the
series of scores calculated at each time point for a given
patient. Starting with the initial table of ISP, four stepswere necessary to identify quality of life change patterns.
These steps are resumed in Additional file 1: Annex 2 and
described below:
1/The first step was a process of data imputation [13, 25]
necessary because of MD. In randomized clinical trials
with QoL assessments, it may be unrealistic to regard
missing data (QoL scores) as due to a not-at-random
mechanism (MCAR or MAR) [11, 12]. Thus, on the
assumption of an MNAR mechanism, we applied the
multiple imputation (MI) method on scores [17]. We
also applied an extension to the longitudinal study of the
explicit multivariate regression method as our imputation
procedure [15, 17, 33]. For this, the auxiliary data (related
to patients) used in the model were as follows: age, time
to death, treatment arm, declaration of severe side effect,
time to treatment failure and previous scores. In practical
terms, the multiple imputation method involves
imputing each missing score several times, say r times.
Without going into technical detail, which can be
found in references [18, 24–28], the imputations are
randomly drawn from a distribution conveniently
derived from the data, taking into account the
relationship between auxiliary variables and the
relationship of each auxiliary variable with the missing
patterns in the remaining ones. Since imputations are
random and not deterministic, a missing score may be
replaced with a different value in each of the r completed
data sets, and therefore the r data sets are not equal. This
operation results in r completed data sets, that is, r data
sets with the same number of variables and participants
as the original one but with all missing values filled in by
imputation. This method may be used for the analysis of
data with large amounts of missing values [18, 24–28].
One hundred datasets with complete ISP were generated
(r = 100). This method finally encompassed the major
part of patients’ quality of life measurement variability.
For the main analysis, scores after death were set to zero
[34, 35].
2/In the second step, variability parameters were
calculated for the 100 imputed datasets. Leffondre et al.
in 2004 proposed 27 statistical measures of change
(renamed parameters in the following) for the
identification of longitudinal patterns [21]. These
parameters concern: i) parameters that described
the linearity of the ISP (e.g. the standard deviation, the
slope of the regression line or the part of the variance
explained by a linear model), ii) those reflecting
non-linearity of the ISP, such as abrupt changes over
short periods (e.g. the mean of successive differences
between 2 consecutive scores), iii) parameters that
measured the contrast between 2 defined periods in an
ISP (ratio between the change before and the change
after) see Additional file 1: Annex 3 for the formula of
Table 1 Characteristics of patients included in the study
Variables ECXa/FOLFIRI arm FOLFIRI/ECX arm
n = 209 n = 207
Gender
Men n (%) 154 (74) 155 (75)
Performance status at D0
=0-1b n (%) 175(83.7) 178(86.0)
=2 n (%) 34(16.3) 29(14.0)
Type of tumor
Diffuse n (%) 46(22.0) 51(24.6)
Age (years)
mdc ± inq 61 ± 16 61 ± 16
Follow-up (months)
md ± inq 9 ± 12 9 ± 10
SAEd n(%)
After 7 evaluation time points 122 (58) 105 (51)
TTFe (weeks)
md ± inq 17 ± 20 22 ± 25
Deaths n(%)
Globalf 175 (84) 180 (87)
After 7 evaluation time points 116 (56) 113 (55)
aECX: Epirubicin-Cisplatin-Capecitabine
bPerformance status
0 = Fully active, able to carry on all pre-disease performance / 1 = Restricted in
physically strenuous activity but ambulatory and able to carry out work of a light
or sedentary nature
2 = Ambulatory and capable of all selfcare but unable to carry out any work
activities. Up and about more than 50 % of waking hours
cmedian ± inter-quartile range
dSerious adverse events
eTime to therapeutic failure of the first-line treatment
fProportion of deaths whatever the therapeutic line
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that included the variability parameters for each ISP.
3/The third step build subgroups (clusters) of ISP,
applying a classification method to each dataset
created. An unsupervised classification technique based
on the « k-means» method, using Euclidian distances
was applied [27, 36]. It addresses the following objective:
given a dataset of n units described by m attributes and a
positive integer k (the number of clusters), group the n
units into k clusters so that the total sum of the distances
of each unit to its nearest cluster center is minimized. To
be able to simultaneously manage both the number of
clusters (k) and the number of features (m) to obtain the
optimal partition, we used a so-called CritCF citerion.
This is a function that expresses the dependency between
k and m (see the complete formula in Additional file 1:
Annex 4). Its goal can be summarized as follows: in the
search space defined by all possible subsets of features in
conjunction with a variable number of clusters, it assigns
a ranking score to each partition that may be defined.
CritCF takes values in range [0,1] and should be
maximized in order to simultaneously obtain the best
feature subset and partition [37].
4/The last step was to classify each patient in the group
that best reflected his/her own QoL change pattern.
This objective was reached by the mean of the aggregation
of the 100 classification results. The aggregation process
was carried out in accordance with a published
methodology [27]. A given patient was assigned to
the change pattern (CP) in which he/she was most
frequently classified within the 100 classifications.
For each CP, a mean ISP was calculated and presented
graphically.
Analysis of sensitivity
The objective here was to evaluate the impact of the
multiple imputation procedure on the final classification
of a patient in one of the CP. For this we represented
each CP graphically as a box plot showing the probabil-
ity of each patient being assigned to one of the classes
from the clustering process on each of the 100 datasets.
This could allow one to observe, for example, if the pa-
tients assigned to the first CP were mainly grouped in
the first cluster. In the second step, we estimated a coef-
ficient of concordance (Adjusted Rand index) between
assignments to different clusters and final assignment to
the corresponding CP. This coefficient was presented
with a mean and its 95 % Confidence Interval [38–40].
Graphical description of QoL change patterns
Each QoL change pattern was described using patients’
characteristics: Demographic data (age and gender),
randomization data (tumor type, location, randomization
arm and World Health Organization (WHO) PerformanceStatus), and follow-up data (TTF, declaration of serious
adverse events (Yes/no), second line treatment adminis-
tration (Switch Yes/no) and the status of the patient (Alive
or dead). These characteristics were presented with bar
charts where each bar corresponded to a modality and the
height was its relative frequency [41].
Frequencies were compared using the Chi-2 test or
Fisher’s exact test when appropriate. The CP were com-
pared using the difference between the maximum and
minimum score (MaxDiff which can be negative if the
first value is the minimum). Continuous quantitative
variables were described as means and standard devia-
tions. For all of the statistical tests, the threshold of
statistical significance was set at 0.05.
SAS version 9.3. was used for all of the statistical
analyses.
Results
The clinical trial randomized 416 patients (209 in ECX/
FOLFIRI and 207 in FOLFIRI/ECX arm, respectively).
Men accounted for the majority of patients in both arms
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14 months of follow-up was approximately 55 %. The
TTF observed were greater in the FOLFIRI/ECX arm
[29]. Table 1 presents the characteristics of patients.
We analyzed 1023 questionnaires from 364 patients, that
is a mean of 3 (SD ± 2) (range 1–12) questionnaires per
patient. Of the first 7 evaluations, 2 912 self-administered
questionnaires (one score for the physical dimension) were
expected given the total number of 416. Considering that
for patients who died, the absence of a score after death
was not MD, we counted 1 262 missing scores, which
corresponds to a proportion of MD of approximately 43 %.
With the process of maximizing the CritCF criterion,
we retained the classification in 4 clusters and only 13
variability parameters (among the 27 initially proposed)
listed in bold case in Additional file 1: Annex 3. These
statistical parameters were selected as the most frequent
as shown in Fig. 1. The corresponding CritCF mean
value was 0.75 (range 0.61-0.87).
The 416 patients were definitively assigned to one of
the 4 QoL change patterns P1, P2, P3 and P4 in the
following proportions: 6 %, 41 %, 19 % and 34 %, re-
spectively. Considering the MaxDiff value, we described
a typology in 3 patterns: an improving pattern (P1) withFig. 1 Distribution of the frequencies for the 27 parameters selected for op
statistical measures used to capture differences for a list of scores collectedMaxDiff = +25 pts, a stability pattern P2 (MaxDiff = −12pts)
and 2 deterioration patterns P3 (MaxDiff = −21pts) and P4
(MaxDiff = −27pts). Figure 2 shows the trend for the mean
scores per QoL change pattern over the 7 evaluation time
points. These trend curves were bordered with curves
showing the standard deviation of the mean scores. Each
QoL change pattern was summarized using classical statis-
tics computed from patients’ available data (age, gender,
randomization arm, performance status, observed death
rate and incidence of serious adverse events) as shown in
Table 2.
Figure 3 shows a much more visual description of the
different patterns according to certain variables. The
TTF variable associated with patients’ status and the in-
formation in Table 2 made it possible to characterize the
4 QoL change patterns. Pattern 1 mostly concerned
patients from the ECX/FOLFIRI arm with equal propor-
tions of living and dead patients. The TTF was between
11 and 31 weeks. In Pattern 2, we had relatively younger
patients (age range [44–66] years old), mostly from
FOLFIRI/ECX arm with the highest TTF (above 31 weeks).
The majority of patient have died. For pattern 3, the ma-
jority of patients experienced serious adverse events and
had the lowest TTF (less than 11 weeks), and pattern 4timal classification in 4 patterns. These parameters (m1 to m27) were
at different time points for each patient
Fig. 2 Representation of the quality of life change patterns over time
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31 weeks. In Patterns 3 and 4, the majority of patients
have died
The impact of the distribution of imputed values is
represented in Fig. 4, which shows the distribution of
the initial ISP clusters for each change pattern. Pattern
2, for example, comprised a majority of patients from
cluster 2 (73 % on average), but also patients from clus-
ter 1 for 15 % and more rarely patients from cluster 3.
In the same way, the concordance coefficient between
each of the 100 classifications and the final assignment
was 0.62 (95% CI [0.61-0.63]) on average.
Discussion
In this work, 3 types of pattern were described: the im-
proving pattern (P1), which had the smallest number of
patients and a maximum difference (MaxDiff ) between
scores of +25 points; the stability pattern (P2), which in-
cluded patients with a mean initial score equal to 80 and
MaxDiff = −12 pts – this was the pattern with the most
patients (41 %); and finally, two deterioration patterns
(P3 and P4) can be distinguish according to the patients’initial score: in the first group with a deterioration
pattern (P3), with the smallest number of patients (78
versus 143), the initial QLQ-C30 physical score was
around 43 while in the second (P4), it was around 82
on the 0–100 scale. And finally, we have proposed a
graphical representation of these patterns. For the vari-
ables collected at inclusion, such as location, type of
tumor, performance status and gender, we found that
the structure of the bar chart was similar whatever the
pattern. However, for the variable, age, the structure
was nuanced with a predominance of the oldest patients
in patterns P1 and P3, and relatively young patients were
predominant in patterns P2 and P4. For variables collected
throughout the study, such as serious adverse events
(complications) or the time to therapeutic failure of the 1st
line therapy (TTF), the structure of the bar chart varied
from one pattern to another.
Our methodological approach was different from the
usual analysis of quality of life. In our work, we aim at
defining distinct patterns of QoL evolution. Further-
more, we observe that each pattern was associated with
a given clinical profile which confirms their pertinence,
Table 2 Characteristics of patients’ QoL change patterns
Pattern 1* Pattern 2 Pattern 3 Pattern 4
Pa
Number of patients 24 171 78 143
Gender
Men n(%) 15 (63) 128 (75) 58 (74) 108 (76) 0.596
Age (years)
md ± inqb 63 ± 17 61 ± 15 65 ± 19 60 ± 17 0.370
Performance status at D0
=0-1c n (%) 20 (83.3) 151 (88.3) 56 (71.8) 126 (88.1) 0.004
=2 n (%) 4 (16.7) 20 (11.7) 22 (28.2) 17 (11.9)
Type of tumor
Diffuse n (%) 7 (29.2) 33(19.3) 22(28.2) 35(24.5) 0.369
Randomization arm
FOLFIRI n (%) 5 (20.8) 93 (54.4) 35 (44.9) 74 (51.8) 0.015
Quality of life Score
Score7-Score1 (p
**) 10.7 (0.520) −13.4 (0.013) −62.7 (0.038) −67.6 (<10−3)
SAEd
n(%) 13 (54) 67 (39) 62 (81) 86 (60) <10−3
TTFe (weeks)
md ± inq 15 ± 18 30 ± 24 4 ± 7 20 ± 12 <10−3
Death
n(%) 3 (13) 18 (11) 78 (100) 131 (92) <10−3
a: p for significance
b:median ± inter-quartile range
cPerformance status
0 = Fully active, able to carry on all pre-disease performance / 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or
sedentary nature
2 = Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50 % of waking hours
dSerious adverse events
etime to therapeutic failure of the first-line treatment
*x-axis: time (unit = weeks) and y-axis: the physical functioning scale scores (range [0–100])
**p for significance of the slope predicted by a linear model
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aim of this paper, and that we did not use any prediction
model, we think that these patterns of QoL may help cli-
nicians to anticipate the course of QoL during cancer
treatment according to the clinical profile. Our explora-
tory work would of course need to be confirmed by fur-
ther results before any clinical use. Pooled clinical trials
may provide a confirmation of the clinical features asso-
ciated with the different patterns in a given diseases so
that clinicians could use such profiles to identify patients
with a low performance status at baseline but who could
present a deterioration in their QoL. Patterns P3 and P4,
for example, included patients with a low performancestatus (quite fully active all pre-disease performance) at
baseline and the occurrence of serious adverse events
(SAE) were associated with a physical QoL pattern of
deterioration and a low baseline score. On the other
hand, clinicians may wish to identify patients who could
present an improvement in their QoL. For example, cli-
nicians could select patients in the ECX arm with TTF
mainly between 11 and 31 weeks as, in our study, we
showed that patients classified in pattern P1 presented
an improvement in their QoL compared with the other
patterns. Clinicians may also want to know which pa-
tients will not have a major change in their QoL. In this
case, they would be interested in selecting patients with
Fig. 3 Description of the different change patterns using variables describing each patient individually
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sified in pattern P2, which showed relative stability in
our study. Of course, the results of this paper would
need to be analyzed further before they could be used to
try and predict the course of QoL during cancer treat-
ment. Future analysis would assess the accuracy of the
model that seeks to predict the course of QoL, based
only on variables that are available at the time that the
prediction is made. Statistics about predictive accuracy
would be provided. Without such an analysis, it is diffi-
cult to ascertain the extent to which a predictive model
would be useful.
Our results are in coherence with the literature. For ex-
ample, Sadighi et al. [5] also found that patients who expe-
rienced a deterioration in their quality of life (pattern P3
in our study) also presented the shortest TTF (<11 weeks)
and had been given ECX as the first-line treatment (ECX/
FOLFIRI arm). In another paper, Curran et al. [4] also
showed that patients who did not present a major change
in their QoL (pattern P2 of stability in our study) had
good clinical results (TTF above 31 weeks) and principally
received irinotecan-based chemotherapy as the first-line
treatment (FOLFIRI/ECX arm).
In this paper, we did not want to exclude patients who
died or to consider them differently according to the
cause of death.. In fact, in these types of clinical trials,
the death rate is very high: most patients with locallyadvanced oeso-gastric cancer die before the first year,
whatever the treatment. As a consequence, the analyses
could not be performed after exclusion of these patients.
For the main analysis, scores after death were set to
zero. We are aware that this is a strong and maybe ques-
tionable hypothesis. Nonetheless, the same kind of as-
sumption is stated when conducting time to degradation
analyses (considering a major decrease of QoL as the
same manner as death and pooling the two events).
It seems important to point out that these results
should not eclipse the strategy used for missing data.
Remember that for each missing score, the imputed
values were chosen to represent both uncertainty about
which values to impute assuming that both the reasons
for non-response and uncertainty about the reasons for
non-response are known. The principal advantage of
using the multiple imputation method is the conserva-
tion of data distribution. In our study, this strategy led
to a model that allowed a more realistic interpretation of
a patient’s life, because it was less biased than the model
we would have obtained using other imputation methods
(using means, last available value, etc.). Nonetheless, this
model still contains a certain number of pitfalls inherent
to the construction of any statistical model. The advantage
of this method was the fact that it produced patterns a
priori independent from other clinical or personal charac-
teristics. This means that it would be possible to analyze
Fig. 4 Visualization for each pattern with regard to the different clusters of patients’ individual score patterns (ISP)
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ables [16] or to search for predictive factors of these
patterns. As a graphical representation makes it easier
for clinicians to interpret the data, the presentation
(bar charts) made it possible to visualize [41] the vari-
ability between the different patterns. This is sometimes
difficult to grasp when it is reduced to standard devia-
tions or confidence intervals alone.
Conclusion
In this work we identified clinical profiles associated with
QoL change over time from clinical trial results. Three
main types of pattern were described: the improving pat-
tern (P1), which had the smallest number of patients and
a maximum difference (MaxDiff) between scores of +25
points; the stability pattern (P2), which included 41 %
of patients, with a mean initial score equal to 80 and
MaxDiff = −12 pts and finally, two deterioration patterns
distinguished according to the patients’ initial score: in the
first group (P3), the initial QLQ-C30 physical score was
around 43 while in the second (P4), it was around 82 on
the 0–100 scale. Our results have laid the foundations fordeeper analyses (notably by studying the sensitivity of the
results). In the future our methodology could be extended
to the analyses of other scales of the EORTC-QLQ-C30
questionnaire, and to other therapeutic trials.
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